Effect of β-tricalcium phosphate coated with zoledronic acid on human osteoblasts and human osteoclasts in vitro

Journal of Biomaterials Applications

Volumn 27, Issue 5, 2013, Pages 577-585

  Kadow Romacker, A ^a   Greiner, S ^a   Schmidmaier, G ^b   Wildemann, B ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

bisphosphonate; L lactide) coating; osteoblast like cells; osteoclast like cells; poly(D; TCP

Indexed keywords

BISPHOSPHONATES; BONE DEFECT; BONE FORMATION; BONE GRAFT; BONE GRAFT MATERIALS; BONE GRAFTING MATERIALS; CELL VIABILITY; COLLAGEN TYPE 1; DRUG CARRIER; HUMAN OSTEOBLAST; IN-VITRO; L-LACTIDE; OPTIMAL BALANCE; OSTEOBLAST-LIKE CELLS; OSTEOCALCIN; OSTEOPROTEGERIN; POLY (D ,L-LACTIDE); POLYMER COATING; STIMULATING EFFECTS; TCP; TRI-CALCIUM PHOSPHATES; ZOLEDRONIC ACID;

BONE; GRAFTING (CHEMICAL); OSTEOBLASTS; PLASTIC COATINGS; POLYMERS;

CELL CULTURE;

BETA-TRICALCIUM PHOSPHATE; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; CALCIUM PHOSPHATE; IMIDAZOLE DERIVATIVE; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; TNFSF11 PROTEIN, HUMAN; ZOLEDRONIC ACID;

ARTICLE; BIOSYNTHESIS; CELL CULTURE; CHEMISTRY; CYTOLOGY; DRUG EFFECT; HUMAN; IN VITRO STUDY; METABOLISM; OSTEOCLAST;

BONE DENSITY CONSERVATION AGENTS; CALCIUM PHOSPHATES; CELLS, CULTURED; DIPHOSPHONATES; HUMANS; IMIDAZOLES; OSTEOCALCIN; OSTEOCLASTS; OSTEOPROTEGERIN; RANK LIGAND;

EID: 80855124906     PISSN: 08853282     EISSN: 15308022     Source Type: Journal    
DOI: 10.1177/0885328211415722     Document Type: Article

References (54)

1. Giannoudis PV, Dinopoulos H, Tsiridis E. Bone substitutes: An update. Injury. 2005 ; 36S: S20 - S27
2. Kurz LT, Garfin SR, Booth RE. Harvesting autogenous iliac bone grafts. A review of complications and techniques. Spine. 1989 ; 14 (12). 1324-1331
3. Sandhu HS, Grewal HS, Parvataneni H. Bone grafting for spinal fusion. Orthop Clin North Am. 1999 ; 30 (4). 685-698
4. Erbe EM, Marx JG, Clineff TD, Bellincampi LD. Potential of an ultraporous beta-tricalcium phosphate synthetic cancellous bone void filler and bone marrow aspirate composite graft. Eur Spine J. 2001 ; 10 (2). S141 - S146
5. LeGeros RZ. Properties of osteoconductive biomaterials: Calcium phosphates. Clin Orthop Relat Res. 2002 ; 395: 81-98
6. Steffen T, Stoll T, Arvinte T, Schenk RK. Porous tricalcium phosphate and transforming growth factor used for anterior spine surgery. Eur Spine J. 2001 ; 10 (2). S132 - S140
7. Keating JF, McQueen MM. Substitutes for autologous bone graft in orthopaedic trauma. J Bone Joint Surg Br. 2001 ; 83 (1). 3-8
8. Neo M, Herbst H, Voigt CF, Gross UM. Temporal and spatial patterns of osteoblast activation following implantation of beta-TCP particles into bone. J Biomed Mater Res. 1998 ; 39 (1). 71-76
9. von Doernberg MC, von Rechenberg B, Bohner M, Grunenfelder S, van Lenthe GH, Muller R, et al. In vivo behavior of calcium phosphate scaffolds with four different pore sizes. Biomaterials. 2006 ; 27 (30). 5186-5198
10. Pioletti DP, Takei H, Lin T, Van Landuyt P, Ma QJ, Kwon SY, et al. The effects of calcium phosphate cement particles on osteoblast functions. Biomaterials. 2000 ; 21 (11). 1103-1114
11. Arinzeh TL, Tran T, Mcalary J, Daculsi G. A comparative study of biphasic calcium phosphate ceramics for human mesenchymal stem-cell-induced bone formation. Biomaterials. 2005 ; 26 (17). 3631-3638
12. LeGeros RZ. Calcium phosphate-based osteoinductive materials. Chem Rev. 2008 ; 108 (11). 4742-4753
13. Hughes DE, MacDonald BR, Russell RG, Gowen M. Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow. J Clin Invest. 1989 ; 83 (6). 1930-1935
14. van Beek ER, Cohen LH, Leroy IM, Ebetino FH, Lowik CW, Papapoulos SE. Differentiating the mechanisms of antiresorptive action of nitrogen containing bisphosphonates. Bone. 2003 ; 33 (5). 805-811
15. Heymann D, Ory B, Gouin F, Green JR, Redini F. Bisphosphonates: New therapeutic agents for the treatment of bone tumors. Trends Mol Med. 2004 ; 10 (7). 337-343
16. Murakami H, Takahashi N, Sasaki T, Udagawa N, Tanaka S, Nakamura I, et al. A possible mechanism of the specific action of bisphosphonates on osteoclasts: Tiludronate preferentially affects polarized osteoclasts having ruffled borders. Bone. 1995 ; 17 (2). 137-144
17. Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Monkkonen J, et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer. 2000 ; 88 (12). 2961-2978
18. Sohara Y, Shimada H, Scadeng M, Pollack H, Yamada S, Ye W, et al. Lytic bone lesions in human neuroblastoma xenograft involve osteoclast recruitment and are inhibited by bisphosphonate. Cancer Res. 2003 ; 63 (12). 3026-3031
19. Allen MR. Bisphosphonates and osteonecrosis of the jaw: Moving from the bedside to the bench. Cells Tissues Organs. 2009 ; 189 (1-4). 289-294
20. Astrand J, Aspenberg P. Topical, single dose bisphosphonate treatment reduced bone resorption in a rat model for prosthetic loosening. J Orthop Res. 2004 ; 22 (2). 244-249
21. Skoglund B, Holmertz J, Aspenberg P. Systemic and local ibandronate enhance screw fixation. J Orthop Res. 2004 ; 22 (5). 1108-1113
22. Amanat N, Brown R, Bilston LE, Little DG. A single systemic dose of pamidronate improves bone mineral content and accelerates restoration of strength in a rat model of fracture repair. J Orthop Res. 2005 ; 23 (5). 1029-1034
23. Amanat N, McDonald M, Godfrey C, Bilston L, Little D. Optimal timing of a single dose of zoledronic acid to increase strength in rat fracture repair. J Bone Miner Res. 2007 ; 22 (6). 867-876
24. Greiner SH, Wildemann B, Back DA, Alidoust M, Schwabe P, Haas NP, et al. Local application of zoledronic acid incorporated in a poly(D,L-lactide) coated implant accelerates fracture healing in rats. Acta Orthop. 2008 ; 79 (5). 717-725
25. Reinholz GG, Getz B, Pederson L, Sanders ES, Subramaniam M, Ingle JN, et al. Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts. Cancer Res. 2000 ; 60 (21). 6001-6007
26. Viereck V, Emons G, Lauck V, Frosch KH, Blaschke S, Grundker C, et al. Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts. Biochem Biophys Res Commun. 2002 ; 291 (3). 680-686
27. Panzavolta S, Torricelli P, Bracci B, Fini M, Bigi A. Alendronate and pamidronate calcium phosphate bone cements: Setting properties and in vitro response of osteoblast and osteoclast cells. J Inorg Biochem. 2009 ; 103 (1). 101-106
28. Schmidmaier G, Wildemann B, Stemberger A, Haas NP, Raschke M. Biodegradable poly(D,L-lactide) coating of implants for continuous release of growth factors. J Biomed Mater Res, Appl Biomat. 2001 ; 58 (4). 449-455
29. Wildemann B, Lubberstedt M, Haas NP, Raschke M, Schmidmaier G. IGF-I and TGF-beta 1 incorporated in a poly(d,l-lactide) implant coating maintain their activity over long-term storage-cell culture studies on primary human osteoblast-like cells. Biomaterials. 2004 ; 25 (17). 3639-3644
30. Greiner S, Kadow-Romacker A, Schmidmaier G, Wildemann B. Cocultures of osteoblasts and osteoclasts are influenced by local application of zoledronic acid incorporated in a poly(D,L-lactide) implant coating. J Biomed Mater Res A. 2009 ; 91 (1). 288-295
31. Risteli L, Risteli J. Biochemical markers of bone metabolism. Ann Med. 1993 ; 25 (4). 385-393
32. Lind M, Overgaard S, Nguyen T, Ongpipattanakul B, Bunger C, Soballe K. Transforming growth factor-beta stimulates bone ongrowth. Hydroxyapatite-coated implants studied in dogs. Acta Orthop Scand. 1996 ; 67 (6). 611-616
33. Boanini E, Torricelli P, Gazzano M, Giardino R, Bigi A. Alendronate-hydroxyapatite nanocomposites and their interaction with osteoclasts and osteoblast-like cells. Biomaterials. 2008 ; 29 (7). 790-796
34. Kajiwara H, Yamaza T, Yoshinari M, Goto T, Iyama S, Atsuta I, et al. The bisphosphonate pamidronate on the surface of titanium stimulates bone formation around tibial implants in rats. Biomaterials. 2005 ; 26 (6). 581-587
35. Valimaki VV, Moritz N, Yrjans JJ, Vuorio E, Aro HT. Effect of zoledronic acid on incorporation of a bioceramic bone graft substitute. Bone. 2006 ; 38: 432-443
36. Garbuz DS, Hu Y, Kim WY, Duan K, Masri BA, Oxland TR, et al. Enhanced gap filling and osteoconduction associated with alendronate-calcium phosphate-coated porous tantalum. J Bone Joint Surg Am. 2008 ; 90 (5). 1090-1100
37. Jakobsen T, Baas J, Kold S, Bechtold JE, Elmengaard B, Soballe K. Local bisphosphonate treatment increases fixation of hydroxyapatite-coated implants inserted with bone compaction. J Orthop Res. 2009 ; 27 (2). 189-194
38. Liu XM, Lee HT, Reinhardt RA, Marky LA, Wang D. Novel biomineral-binding cyclodextrins for controlled drug delivery in the oral cavity. J Control Release. 2007 ; 122 (1). 54-62
39. Faucheux C, Verron E, Soueidan A, Josse S, Arshad MD, Janvier P, et al. Controlled release of bisphosphonate from a calcium phosphate biomaterial inhibits osteoclastic resorption in vitro. J Biomed Mater Res A. 2009 ; 89 (1). 46-56
40. Long KA, Jackson JK, Yang C, Chehroudi B, Brunette DM, Burt HM. Controlled release of alendronate from polymeric films. J Biomater Sci Polym Ed. 2009 ; 20 (5-6). 653-672
41. Greiner S, Kadow-Romacker A, Wildemann B, Schwabe P, Schmidmaier G. Bisphosphonates incorporated in a poly(D,L-lactide) implant coating inhibit osteoclast like cells in vitro. J Biomed Mater Res A. 2007 ; 83 (4). 1184-1191
42. Schmidmaier G, Schwabe P, Strobel C, Wildemann B. Carrier systems and application of growth factors in orthopaedics. Injury. 2008 ; 39 (2). S37 - S43
43. Schmidmaier G, Wildemann B, Bail H, Lucke M, Fuchs T, Stemberger A, et al. Local application of growth factors (insulin-like growth factor-1 and transforming growth factor-β1) from a biodegradable poly(D,L-lactide) coating of osteosynthetic implants accelerates fracture healing in rats. Bone. 2001 ; 28 (4). 341-350
44. Greiner S, Kadow-Romacker A, Lubberstedt M, Schmidmaier G, Wildemann B. The effect of zoledronic acid incorporated in a poly(D,L-lactide) implant coating on osteoblasts in vitro. J Biomed Mater Res A. 2007 ; 80 (4). 769-775
45. Schmidmaier G, Wildemann B, Lübberstedt M, Haas NP, Raschke M. IGF-I and TGF-beta 1 incorporated in a poly(D,L-lactide) implant coating stimulates osteoblast differentiation and collagen-1 production but reduces osteoblast proliferation in cell culture. J Biomed Mater Res, Appl Biomat. 2003 ; 65b: 157-162
46. D'Aoust P, McCulloch CA, Tenenbaum HC, Lekic PC. Etidronate (HEBP) promotes osteoblast differentiation and wound closure in rat calvaria. Cell Tissue Res. 2000 ; 302 (3). 353-363
47. Stadelmann VA, Gauthier O, Terrier A, Bouler JM, Pioletti DP. Implants delivering bisphosphonate locally increase periprosthetic bone density in an osteoporotic sheep model. A pilot study. Eur Cell Mater. 2008 ; 16: 10-16
48. Im GI, Qureshi SA, Kenney J, Rubash HE, Shanbhag AS. Osteoblast proliferation and maturation by bisphosphonates. Biomaterials. 2004 ; 25 (18). 4105-4115
49. Pan B, To LB, Farrugia AN, Findlay DM, Green J, Gronthos S, et al. The nitrogen-containing bisphosphonate, zoledronic acid, increases mineralisation of human bone-derived cells in vitro. Bone. 2004 ; 34 (1). 112-123
50. Orriss IR, Key ML, Colston KW, Arnett TR. Inhibition of osteoblast function in vitro by aminobisphosphonates. J Cell Biochem. 2009 ; 106 (1). 109-118
51. Simon MJ, Niehoff P, Kimmig B, Wiltfang J, Acil Y. Expression profile and synthesis of different collagen types I, II, III, and V of human gingival fibroblasts, osteoblasts, and SaOS-2 cells after bisphosphonate treatment. Clin Oral Investig. 2010 ; 14 (1). 51-58
52. Josse S, Faucheux C, Soueidan A, Grimandi G, Massiot D, Alonso B, et al. Novel biomaterials for bisphosphonate delivery. Biomaterials. 2005 ; 26 (14). 2073-2080
53. Teitelbaum SL. Bone resorption by osteoclasts. Science. 2000 ; 289 (5484). 1504-1508
54. Koch FP, Merkel C, Ziebart T, Smeets R, Walter C, Al Nawas B. Influence of bisphosphonates on the osteoblast RANKL and OPG gene expression in vitro. Clin Oral Investig. 2010 ;: